SEC Tracker
Get the app

Arcutis Biotherapeutics ARQT

Robert Lisicki reports ownership change

Robert Lisicki, new insider at ARQT

Form
3
Filed
Importance
Routine
  1. Robert Lisicki, EVP, owns 55,000 common shares
  2. Lisicki has 145,000 stock options expiring Aug 17, 2036
  3. Options vest monthly starting Aug 17, 2026

Written from the Form 3 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Arcutis Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  2. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  3. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old
  4. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025